CHRS - Coherus BioSciences, Inc. Price-to-Projected Revenue Ratio

Coherus (CHRS) - corporate logo

Intense competition in the biosimilars sector is forcing Coherus Biosciences (CHRS) to offer significant discounts to insurers, which increases operating expenses. The projected P/S trend visualizes this balance, while the 1.50 metric confirms the current valuation level. Meanwhile, the company maintains premium pricing for innovative drugs, leveraging high macro-resilience and stable demand in oncology.

Coherus BioSciences Inc. - CHRS Projected Price to Revenue (period 07/04/2022 - 11/16/2026)

Comprehensive metric breakdowns and analytics for Coherus BioSciences (CHRS)

- market price and analyst price targets:
General company analysis:Coherus BioSciences, Inc. CHRS
Manufactured products of coherus.com

Using forward multiples minimizes the impact of market volatility, allowing for a valuation of Coherus Biosciences (CHRS) based on expected biosimilar and oncology drug sales. By analyzing the forward P/S ratio dynamics on the GURU.Markets platform, an investor can see the relationship between current market capitalization and future revenue, which helps determine the extent to which the market has priced in the expansion potential of the company's pharmaceutical products.